Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Research & Development (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Research & Development for 13 consecutive years, with $642000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 24.02% to $642000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 21.76% decrease, with the full-year FY2025 number at $3.0 million, down 21.76% from a year prior.
  • Research & Development was $642000.0 for Q4 2025 at Ekso Bionics Holdings, up from $549000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.4 million in Q2 2023 to a low of $549000.0 in Q3 2025.
  • A 5-year average of $910050.0 and a median of $920500.0 in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 56.86% in 2021, then plummeted 35.64% in 2024.
  • Ekso Bionics Holdings' Research & Development stood at $619000.0 in 2021, then soared by 52.83% to $946000.0 in 2022, then skyrocketed by 38.79% to $1.3 million in 2023, then tumbled by 35.64% to $845000.0 in 2024, then dropped by 24.02% to $642000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Research & Development are $642000.0 (Q4 2025), $549000.0 (Q3 2025), and $852000.0 (Q2 2025).